BioSpace News Archive

Amarin Corporation plc (NASDAQ:AMRN) and Neopharm Israel announced today that the two companies have entered into an exclusive marketing and commercialization agreement for VAZKEPA® (icosapent ethyl) in the State of Israel, Gaza, West Bank and the territories of the Palestinian Authority.

Astex Pharmaceuticals announced an exclusive worldwide research collaboration and license agreement with MSD.

GenScript Biotech Corporation, the world’s leading provider of life-science research tools and services, has ramped up production of complex and modified peptides at its state-of-the-art cGMP manufacturing facility in Zhenjiang, China.

Oculis Holding AG announced positive top line results from its Phase 3 OPTIMIZE trial with OCS-01 eye drops, a novel, once-daily, high concentration, preservative-free, topical OPTIREACH® formulation of dexamethasone for the treatment of inflammation and pain following ocular surgery.

RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 363 owned and operated outpatient imaging centers, reported financial results for its second quarter of 2023.

Zomedica Corp. announced Larry Heaton, CEO, will present and host one-on-one meetings with investors at the Sidoti August Virtual Investor Conference, taking place on August 16-17, 2023.

Bio-Techne Corporation reported its financial results for the fourth quarter ended June 30, 2023.

ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter 2023 and provided business updates.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, provided an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma.

SYSNAV Healthcare announces that the European Medicines Agency considers that for ambulant Duchenne Muscular Dystrophy patients four years of age and above, Stride Velocity 95th centile qualifies as primary endpoint in superiority studies as an alternative to the 6 Minute Walking Test provided this outcome measure is supported by consistent findings in established efficacy endpoints included in secondary endpoints.